Prelude Therapeutics (PRLD) Non-Current Deffered Revenue (2025)
Prelude Therapeutics (PRLD) reported Non-Current Deffered Revenue of $1.8 million for Q4 2025.
Prelude Therapeutics (PRLD) Non-Current Deffered Revenue (2025) Analysis & Trends
Prelude Therapeutics (PRLD) has 1 years of Non-Current Deffered Revenue data on file, last reported at $1.8 million in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Deffered Revenue changed N/A year-over-year to $1.8 million; the trailing twelve-month figure through Dec 2025 stood at $1.8 million (changed N/A YoY), and the FY2025 full-year result was $1.8 million, changed N/A from the prior year.
- Non-Current Deffered Revenue steadied at $1.8 million in Q4 2025.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $1.8 million in Q4 2025 to a low of $1.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Prelude Therapeutics | 324.30 Mn | 179.71 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.80 Mn |